PEETERS ONLINE JOURNALS
Peeters Online Bibliographies
Peeters Publishers
this issue
  previous article in this issuenext article in this issue  

Document Details :

Title: Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation
Author(s): D.-A. Pei , Y.-Y. Yan , L. Li , Z.-Y. Xu , J.-Y. Huang , M. Wang , Z.-M. Xu , Q. Yao , S.-E. Huang , Q. Huang , S.-S. Wang
Journal: Acta Cardiologica
Volume: 65    Issue: 5   Date: 2010   
Pages: 527-533
DOI: 10.2143/AC.65.5.2056239

Abstract :
Objective — Atrial fibrillation is associated with the activation of the renin-angiotensin-aldosterone system in the atria. It is not clear whether the expression of mineralocorticoid receptor (MR) and aldosterone synthase CYP11B2 in patients with atrial fibrillation is altered. This study aimed to investigate the mRNA expression of MR and CYP11B2 and to reveal the correlation between CYP11B2 mRNA and matrix remodelling in patients with atrial fibrillation.
Methods — Twenty-five patients with rheumatic heart valve disease, 12 in sinus rhythm and 13 in atrial fibrillation (> 6 months), underwent a valve replacement operation and right and left atrial lateral wall tissue samples were obtained. The MR and CYP11B2 expressions were analysed at the mRNA level and collagen volume fraction was determined by Van Gieson’s staining.
Results — Collagen volume fraction was found to be increased significantly in atrial fibrillation groups compared with sinus rhythm groups (P < 0.001). Both the mRNA of MR and CYP11B2 were significantly increased in the fibrillation group compared with the group in sinus rhythm (P < 0.01). Collagen volume fraction significantly and positively correlated with left atrial dimension (r = 0.845, P < 0.001). There was a positive correlation between CYP11B2∞∞mRNA and collagen volume fraction (r = 0.757, P < 0.001).
Conclusion — Increased expression of MR and CYP11B2 in the atria is one of the molecular mechanisms for the development of atrial interstitial fibrosis in patients with atrial fibrillation.

3.234.211.61.